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Introduction
Rapid weight gain during the first few 
months of life is a predictor for later obesity 
(Monteiro and Victora 2005). Perinatal 
exposure to chemicals may contribute to 
obesity by affecting endocrine and neuronal 
pathways (La Merri l l  and Birnbaum 
2011). Polychlorinated biphenyls (PCBs), 
p,p´‑dichloro diphenyltr ichloroethane 
(p,p´‑DDT) and metabolite p,p´‑dichloro‑
diphenyl dichloroethylene (p,p´‑DDE) 
were used in agriculture and industry until 
global efforts in the 1990s to eliminate them 
(Stockholm Convention 2001). Substantial 
exposure is still observed due to the persistency 
of these lipophilic compounds (Longnecker 
et al. 2003). PCB‑153 has a biological half‑
life of about 14 years (Ritter et al. 2011), and 
p,p´‑DDE about 13 years (Wolff et al. 2000).
Epidemiological studies on perinatal 
POPs exposure, growth, and obesity have 
focused on transplacental exposure, with 
inconsistent results for PCB and a predomi‑
nantly positive association for p,p´-DDE 
(reviewed by Cupul‑Uicab et al. 2013). 
However, substantial exposure occurs post‑
natally through breastfeeding, research on 
which is limited (Grandjean et al. 2003; 
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Background: Infant exposure to persistent organic pollutants (POPs) may contribute to obesity. 
However, many studies so far have been small, focused on transplacental exposure, used an inappro-
priate measure to assess postnatal exposure through breastfeeding if any, or did not discern between 
prenatal and postnatal effects.
oBjectives: We investigated prenatal and postnatal exposure to POPs and infant growth 
(a predictor of obesity). 
Methods: We pooled data from seven European birth cohorts with biomarker concentrations of 
polychlorinated biphenyl 153 (PCB-153) (n = 2,487), and p,p´-dichlorodiphenyldichloroethylene 
(p,p´-DDE) (n = 1,864), estimating prenatal and postnatal POPs exposure using a validated 
pharmaco kinetic model. Growth was change in weight-for-age z-score between birth and 
24 months. Per compound, multilevel models were fitted with either POPs total exposure from 
conception to 24 months or prenatal or postnatal exposure. 
results: We found a significant increase in growth associated with p,p´-DDE, seemingly due to 
prenatal exposure (per interquartile increase in exposure, adjusted β = 0.12; 95% CI: 0.03, 0.22). 
Due to heterogeneity across cohorts, this estimate cannot be considered precise, but does indicate 
that an association with infant growth is present on average. In contrast, a significant decrease in 
growth was associated with postnatal PCB-153 exposure (β = –0.10; 95% CI: –0.19, –0.01).
conclusion: To our knowledge, this is the largest study to date of POPs exposure and infant 
growth, and it contains state-of-the-art exposure modeling. Prenatal p,p´-DDE was associ-
ated with increased infant growth, and postnatal PCB-153 with decreased growth at European 
exposure levels.
citation: Iszatt N, Stigum H, Verner MA, White RA, Govarts E, Palkovicova Murinova L, 
Schoeters G, Trnovec T, Legler J, Pelé F, Botton J, Chevrier C, Wittsiepe J, Ranft U, 
Vandentorren S, Kasper-Sonnenberg M, Klümper C, Weisglas-Kuperus N, Polder A, Eggesbø M, 
OBELIX. 2015. Prenatal and postnatal exposure to persistent organic pollutants and infant growth: 
a pooled analysis of seven European birth cohorts. Environ Health Perspect 123:730–736; http://
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Jacobson et al. 1990; Pan et al. 2010; 
Patandin et al. 1998; Rogan et al. 1987). 
Most studies were limited by sample size 
and had no or incomplete postnatal exposure 
[assessed using the product of persistent 
organic pollutants (POPs) concentration and 
breastfeeding duration]. Postnatal exposure 
needs to be considered but is challenging 
because multiple factors such as child growth 
and maternal weight gain also influence chil‑
dren’s internal concentrations.
In the largest study to date on POPs and 
growth, we pooled data from seven European 
birth cohorts to investigate the associa‑
tion between prenatal and postnatal POPs 
exposure and infant growth from birth to 
24 months in singleton term children, and 
used a recently developed pharmacokinetic 
model (Verner et al. 2013) to improve post‑
natal exposure assessment.
Methods
Description of cohorts. Previously, Govarts 
et al. (2012) identified 14 cohorts of mother–
child pairs with POPs measures from the 
Environmental Health Risks in European 
Birth Cohorts’ (ENRIECO) inventory (http://
www.enrieco.org/). Eleven of these cohorts had 
relevant weight data and were invited to partic‑
ipate. Four [FAROES2, FAROES3, INMA 
(INfancia y Medio Ambiente; Environment 
and Childhood), Rhea] did not participate 
for reasons unrelated to this study hypothesis. 
Seven cohorts (n = 2,487) had PCB‑153, and 5 
cohorts (n = 1,864) had p,p´-DDE biomarkers. 
Concentrations were measured in cord serum/
plasma in FLEHS I (Flanders Environment 
& Health Survey) (Koppen et al. 2009), 
GRD (Groningen–Rotterdam–Düsseldorf) 
(Huisman et al. 1995, Walkowiak et al. 2001), 
Michalovce (Hertz‑Picciotto et al. 2003), 
and PELAGIE (Perturbateurs endocriniens: 
Étude Longitudinale sur les Anomalies de la 
Grossesse, l’Infertilité et l’Enfance) (Chevrier 
et al. 2013); in breast milk in ELFE (Growing 
up in France) (Vandentorren et al. 2009) and 
HUMIS (Norwegian Human Milk Study) 
(Eggesbø et al. 2009); and in maternal blood 
during pregnancy in Duisburg (Wilhelm et al. 
2008, Wittsiepe et al. 2008). Table 1 lists 
population characteristics, and Supplemental 
Material, Table S1, contains cohorts’ descrip‑
tions and references. Each study was approved 
by national ethical committees. Mothers 
provided written informed consent prior 
to participation.
Exposure assessment. All cohorts provided 
lipid‑adjusted and wet‑weight concentra‑
tions, plus information on lipid measure‑
ment (see Supplemental Material, Table S2). 
We replaced POP concentrations below the 
limit of detection/quantification (LOD/
LOQ) (Table 2; see also Supplemental 
Material, Table S2) with LOD/LOQ divided 
by the square root of two (Hornung and 
Reed 1990).
We estimated individual‑specific cord 
blood concentration (prenatal exposure) 
and cumulative postnatal exposure using a 
validated pharmacokinetic model (Verner 
et al. 2013). Two compartments repre‑
senting maternal and child lipids are 
connected through placental diffusion 
and excretion/intake of breast milk (see 
Supplemental Material, Figure S1A). To 
generate individual‑specific profiles of child 
POPs concentrations (e.g., see Supplemental 
Material, Figure S1B), the pharmacokinetic 
model incorporated maternal age, prepreg‑
nancy weight, gestational age, sex, child’s 
weight at birth and several time points, 
and total breastfeeding duration (exclusive/
partial). We used fixed values for gestational 
weight gain and postpartum maternal weight 
(Verner et al. 2013) because this information 
was not collected in some cohorts and there‑
fore could not be imputed within cohort‑
specific multiple imputation models, in 
contrast with missing data for other covariates 
(see below). Most studies did not distinguish 
exclusive from partial breastfeeding; there‑
fore, we used total breastfeeding duration. 
Breast milk consumption rate was based on 
exclusive/partial breastfeeding data from 
the general population (Arcus‑Arth et al. 
2005). Measured POP concentrations in 
maternal blood, cord blood, or breast milk 
(nanograms per gram lipids) were used to 
estimate  individual‑specific maternal daily 
dose and subsequently to simulate complete 
time course of child concentrations: Iterative 
model simulations adjusting the maternal 
daily dose provided matching simulated 
and measured blood or breast milk POP 
 concentrations at the time of collection.
We abstracted the simulated cord 
blood concentration at delivery as the 
common prenatal exposure estimate across 
cohorts (vs. measures taken in different 
biological matrices sampled at different 
times). We calculated postnatal cumulative 
exposure 0–24 months as area under the 
curve (AUC) (see Supplemental Material, 
Figure S1B). We added prenatal (multiplied 
by gestational age) to postnatal to get total 
exposure from conception to 24 months. 
The three exposure metrics are expressed as 
average concentrations over their respective 
time periods (nanograms per gram lipids). 
Model simulations were performed using 
acsIX (Aegis Technologies Group Inc., 
Huntsville, AL, USA).
Outcome variable. Cohorts provided 
weight and height data with minimum two 
time points after birth to 3 years. Michalovce 
had data up to 4 years, Duisburg had data 
at 1.5 and 6.5 years. Weight and height 
data were measured for the study by nurses 
or doctors (GRD, Michalovce) or recorded 
during pediatric examinations in children’s 
health cards that were obtained by study 
staff (FLEHS I) or were parent‑reported 
(Duisburg, ELFE, HUMIS, PELAGIE). 
We estimated weight at exactly 24 months 
using a cohort‑specific, sex‑specific, multi‑
level (mixed) linear model fitted with 
cubic polynomials and random effects for 
infant. We then created cohort‑specific, 
sex‑specific, weight‑for‑age z‑scores at birth 
and 24 months. Intraclass correlations 
between predicted and observed values at 
24 months (± 14 days) in infants with avail‑
able data ranged from 0.84 (ELFE males) to 
≥ 0.90 (ELFE females, FLEHS I, HUMIS, 
PELAGIE). GRD, Michalovce, and Duisburg 
had no children with observed data at 
24 months. The difference between the child’s 
z‑score at birth and 24 months (change in 
weight‑for‑age z‑score) was analyzed as a 
continuous outcome.
Statistical analysis. We imputed missing 
data (outcome, exposure, covariate) by 
cohort, using multiple imputation by chained 
equations (ICE) (Rubin 1987; van Buuren 
2007), and performed pharmacokinetic 
model simulations for each imputation set. 
The pharmacokinetic model used lipid‑
adjusted concentrations because they are 
more stable over time (Phillips et al. 1989). 
Some observations in all cohorts except ELFE 
and HUMIS were missing lipid‑adjusted 
concentrations, and these were imputed 
in a cohort‑specific model including wet‑
weight concentrations. We assessed corre‑
lations between exposures and covariates 
using Pearson’s correlation coefficients. We 
combined exposure, outcome, and covariate 
data from individual cohorts into a pooled 
data set to analyze as a single data set, using a 
multilevel (mixed) linear regression model to 
estimate associations between infant growth 
and separately, total, prenatal, and postnatal 
exposure. For each compound, we tested for 
heterogeneity by fitting a model with random 
intercepts and slopes by cohort. There was 
significant heterogeneity for all exposures (see 
Supplemental Material, Table S3). However, 
in the case of p,p´‑DDE, which was avail‑
able in only five cohorts, we had less power 
to fit a complex model [i.e., confidence 
intervals (CIs) were severely inflated; see 
Supplemental Material, Table S4]. Therefore, 
models were fitted with random intercepts 
for p,p´-DDE, and random intercepts and 
slopes for PCB‑153. Models were fitted via 
maximum likelihood, using the STATA 12.0 
“mi estimate” function to pool five impu‑
tation results. For prenatal and postnatal 
exposure, models were fitted first with either 
prenatal or postnatal concentrations in the 
model and then with both (prenatal and 
postnatal mutually adjusted). We checked 
Iszatt et al.
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Table 1. Characteristics of the cohorts [median (range) or n (%)].
Characteristic
Duisburg 
(Germany, 
2000–2002) 
(n = 222)
ELFE  
(France, 
2007) 
(n = 35)
FLEHS I 
(Belgium, 
2002–2004) 
(n = 134)
GRD 
(Germany, Netherlands, 
1990–1995) 
(n = 588)
HUMIS 
(Norway, 
2002–2006)  
(n = 399)
Michalovce 
(Slovakia, 
2002–2004) 
(n = 938)
PELAGIE 
(France, 
2002–2006) 
(n = 171)
Change in weight-for-age 
z-score 0–24 months
–0.13 (–2.74–4.83) 0.06 (–2.38–2.21) 0.04 (–2.59–3.40) –0.03 (–3.87–3.46) –0.03 (–3.91–3.83) –0.01 (–5.01–3.72) 0.03 (–2.85–3.63)
Missing (%) 0 0 0 0 1 3 0
Weight 24 m (kg) 13.56 (10.35–17.50) 12.00 (9.93–13.47) 12.53 (10.01–15.87) 13.21 (9.89–18.54) 12.19 (8.36–18.49) 13.66 (10.08–20.26) 12.39 (8.86–16.78)
Missing (%) 0 0 0 0 1 2 0
Height 24 m (cm) 87.4 (76.6–95.8) 87.6 (82.9–104.7) 88.0 (77.7–94.4) 88.6 (80.5–98.1) 86.3 (71.2–108.3) 86.2 (74.9–96.3) 87.5 (78.8––96.3)
Missing (%) 0 0 0 0 1 2 0
Birth weight (g) 3.460 (1.960–4.925) 3.340 (2.800–4.110) 3.383 (2.600–4.530) 3.500 (2.140–5.000) 3.680 (2.030–5.100) 3.370 (2.060–5.060) 3.370 (2.320–4.760)
Missing (%) 0 0 0 0 0 3 0
Birth length (cm) 52 (42–61) 49 (47–52) 50.7 (48.2–53.1) 52.5 (44–60) 51 (42–55) 50 (40–57) 50 (43–55)
Missing (%) 0 0 0 0 10 22 0
Gestational age (weeks) 40 (37–42) 40 (38–41) 40 (37–41) 40 (37–43) 40 (37–44) 40 (37–43) 40 (37–42)
Missing (%) 1 0 0 0 5 10 0
Sex
Male 108 (48.7) 18 (51.4) 72 (53.7) 322 (54.8) 203 (51.1) 477 (51.0) 92 (53.8)
Female 114 (51.4) 17 (48.6) 62 (46.3) 266 (45.2) 195 (49.0) 459 (49.0) 79 (46.2)
Missing (%) 0 0 0 0 1 2 0
Maternal age (years) 31.9 (19.3–42.6) 32.9 (24.3–41.3) 31.1 (20.3–41.1) 29 (18–40) 29 (16–42) 25.7 (17.9–45) 31.1 (20.1–45)
Missing (%) 0 0 0 0 0 11 0
Maternal prepregnancy BMI 23.0 (14.9–51.4) 21.5 (18.1–27.7) 22.4 (16.9–37.4) 22.1 (15.0–48.3) 23.3 (16.6–43.8) 21.2 (14.5–40.7) 21.9 (17.3–37.6)
Missing (%) 0 1 1 1 6 44 0
Maternal prepregnancy 
weight (kg)
65 (42–140) 58 (47–78) 62 (45–112) 64 (44–133) 66 (43–120) 58 (38–115) 58 (46–105)
Missing (%) 0 0 1 1 4 44 0
Maternal gestational weight 
gain (kg)
NA NA 15.0 (1.0–30.0) NA 14.0 (–3.0–31.0) 14.0 (1.0–35.0) 13.0 (5.0–31.0)
Missing (%) 222 35 60 588 8 250 0
Maternal height (cm) 168 (151–183) 163 (148–173) 168 (150–183) 170 (150–193) 168 (149–199) 165 (133–186) 165 (150–190)
Missing (%) 0 1 1 0 3 0 0
Parity
0 0 (0.0) 12 (34.3) 84 (62.7) 294 (50.0) 154 (38.6) 391 (41.7) 68 (39.8)
≥ 1 222 (100.0) 23 (65.7) 50 (37.3) 294 (50.0) 245 (61.4) 547 (58.3) 103 (60.2)
Missing (%) 0 0 0 0 0 1 0
Education
Low 50 (22.5) 1 (2.9) 5 (3.7) 73 (12.4) 53 (13.4) 177 (19.0) 29 (17.0) 
Medium 83 (37.4) 8 (22.9) 96 (73.3) 184 (31.4) 253 (64.1) 687 (73.7) 26 (15.2) 
High 89 (40.1) 26 (74.3) 30 (22.9) 330 (56.2) 89 (22.5) 68 (7.3) 116 (67.84)
Missing (%) 0 0 3 1 4 6 0
Maternal smoking during 
pregnancya
No 169 (76.1) 33 (100.0) 120 (90.2) 438 (74.5) 357 (89.5) 805 (85.8) 137 (80.6)
Yes 53 (23.9) 0 13 (9.8) 150 (25.5) 42 (10.5) 133 (14.2) 33 (19.4)
Missing (%) 0 2 1 0 0 0 1
Ethnicity
Caucasian 211 (95.1) NA NA 588 (100.0) 374 (98.2) 738 (80.7) 171 (100.0)
Inuit 0 NA NA 0 2 (0.5) 0 0
Roma 0 NA NA 0 1 (0.3) 177 (19.3) 0
Other 11 (5.0) NA NA 0 4 (1.1) 0 0
Missing (%) 0 35 134 0 17 23 0
Sample type
Maternal blood 216 0 0 0 0 0 0
Cord blood 0 0 130 267 0 880 168
Breast milk 0 35 0 321 399 0 0
Missing (%) 6 0 4 0 0 58 3
Sample collection time (days 
from birth)
–51 (–107–42) 51 (36–70) 0 (0–0) CB: 0 (0–0)  
BM: 14 (14–14) 
32 (2–158) 0 (0–0) 0 (0–0)
Missing (%) 6 0 4 0 18 58 3
Total breastfeeding (months) 6.9 (0.2–18) 5.0 (1.6–23) 3 (0–48) 2.3 (0–6) 12 (1–31.2) 5 (0–48) 3.1 (0–24.8)
Missing (%) 38 2 42 5 0 5 8
No breastfeeding 0 (0) 0 (0) 34 (25.4) 224 (38.1) 0 (0) 2 (0.2) 70 (40.9)
Missing (%) 38 2 42 5 0 5 8
Exclusive breastfeeding 
(months)
4.8 (0–9.9) NA 0 (0–1) NA 5 (0–10) 3 (0–12) NA 
Missing (%) 39 35 76 588 0 3 171
Abbreviations: BM, breast milk; CB, cord blood; ELFE, Etude Longitudinale Française depuis l’Enfance (French Longitudinal Study of Children); FLEHS I, Flemish Environment and Health 
Survey I; GRD, Groningen–Rotterdam–Düsseldorf; HUMIS, Human Milk Study; NA, not available; PELAGIE, Endocrine disruptors: longitudinal study on pathologies of pregnancy, infer-
tility and childhood. Continuous measures described by median (minimum–maximum); categorical measures described by frequencies (%).
aIn PELAGIE, smoking status at inclusion was used as proxy for smoking during pregnancy. 
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for collinearity between prenatal and post‑
natal exposure with variance inflation factors 
(VIFs) greater than 5 to 10, suggesting 
a problem with collinearity (Kleinbaum 
et al. 2013).
We identified nine potential confounders 
and intermediate covariates a priori using 
directed acycl ic  graphs (DAGs) (see 
Supplemental Material, Figures S2A,B,C for 
total, prenatal, and postnatal exposure DAGs, 
respectively): maternal prepregnancy body 
mass index (BMI, continuous), maternal 
age (years, continuous), education (low, 
medium, high), smoking during pregnancy 
(yes/no), Roma ethnicity (yes/no), nulliparous 
(yes/no), gestational age (weeks, continuous), 
birth weight (kilograms, continuous), total 
breastfeeding (months, continuous), maternal 
gestational weight change (kilograms). 
Categories for primary and secondary educa‑
tion varied, so we combined categories to 
create relative low, medium, and high per 
cohort. ELFE and FLEHS I had no ethnicity 
information (important due to a large Roma 
population in Michalovce), so we assumed 
their ethnicity was not Roma. We made 
additional adjustment for maternal gesta‑
tional weight change in FLEHS I, HUMIS, 
PELAGIE, and Michalovce. Similarly, we 
assessed the results’ sensitivity to maternal 
consumption of fatty fish (meals/week 
HUMIS, FLEHS I) and total fish (grams/
week, PELAGIE, MICHALOVCE) by 
adjusting for these covariates.
We looked at the effect of removing each 
cohort in turn. We assessed assumptions of 
normality and linearity using informal diag‑
nostic plots, and assessed the combination 
of high leverage and residuals in order to fit 
regression models with and without influential 
observations. Results are change in weight‑for‑
age z‑score from birth to 24 months for the 
interquartile range (IQR) of exposure.
Results
Table 1 summarizes cohort characteristics. 
Duisburg infants were the slowest and ELFE 
infants the fastest growers. Total breast‑
feeding duration varied (2.3–12 months), as 
did number of infants with no breastfeeding: 
Duisburg, ELFE, and HUMIS had none; 
Michalovce, 0.2%; FLEHS I, 25.4%; GRD, 
38.1%; and PELAGIE, 40.9%.
Table 2 shows estimated prenatal and 
postnatal infant blood POPs concentrations. 
For prenatal concentrations, PELAGIE was 
lowest and GRD highest for PCB‑153, and 
HUMIS lowest and Michalovce highest 
for p,p´‑DDE. PELAGIE had lowest post‑
natal exposures, whereas ELFE had highest 
PCB‑153 and Michalovce highest p,p´-DDE. 
Measured biomarker concentrations were 
not substantially different from the estimated 
cord blood (prenatal) concentrations (see 
Supplemental Material, Table S5).
Prenatal and postnatal exposures were 
highly correlated (PCB‑153 r = 0.71, 
p,p´-DDE r = 0.88; see Supplemental Material, 
Table S6), although this varied across the 
cohorts. Overall correlations between prenatal 
PCB‑153/p,p´-DDE concentrations were 
moderate (r = 0.65), varying from r = 0.11 
to r = 0.65 across cohorts (data not shown), 
whereas correlations between total breast‑
feeding and postnatal POPs exposure were 
lower (PCB‑153 r = 0.43, p,p´-DDE r = 0.31) 
(see Supplemental Material, Table S6).
VIFs for prenatal and postnatal exposure 
in the same model varied across cohorts 
from low (i.e., FLEHS I, PELAGIE) to 
high (i.e., HUMIS, ELFE), and were < 5 
for the pooled data set (see Supplemental 
Material, Table S7).
Table 3 shows the relation between total 
exposure from conception to 24 months and 
infant growth. Individual cohort analyses 
showed significant associations only for GRD 
(PCB‑153) and Duisburg (p,p´-DDE). The 
pooled data showed nonsignificant associations 
between change in weight‑for‑age z‑score and 
PCB‑153 (β = –0.06; 95% CI: –0.15, 0.03 
for an IQR increase of 152 ng/g lipid) and 
p,p´-DDE (β = 0.04; 95% CI: –0.001, 0.07 
for an IQR increase of 515 ng/g lipid).
Figure 1 shows the secondary analyses 
assessing which of prenatal and postnatal 
exposure is the more important contributor 
toward associations with total exposure. After 
adjustment for prenatal exposure, postnatal 
PCB‑153 was associated with a significant 
decrease in change in weight‑for‑age z‑score 
(β = –0.10; 95% CI: –0.19, –0.01 for an 
IQR increase of 183 ng/g lipid) (Figure 1A). 
Prenatal p,p´-DDE was associated with a 
significant increase in change in weight‑for‑age 
z‑score (β = 0.12; 95% CI: 0.03, 0.22 for an 
increase of 388 ng/g lipid) after  adjustment for 
postnatal exposure (Figure 1B).
In general, leaving out one cohort did not 
have a substantial influence on the prenatal 
and postnatal pooled estimates, with point 
estimates for the partial sample within the 
CI of the overall pooled result. However, for 
prenatal p,p´‑DDE, removing Michalovce 
doubled the estimate (from 0.12; 95% CI: 
0.03, 0.22 to 0.23; 95% CI: –0.09, 0.54) 
and made it nonsignificant (see Supplemental 
Material, Table S8).
Additional adjustment for fish consump‑
tion or maternal gestational weight change 
did not materially affect results (data not 
shown). Complete case and multiple imputa‑
tion analyses gave essentially the same results, 
as did estimates of prenatal exposure from 
biomarker concentrations and pharmaco‑
kinetic modeled estimations (see Supplemental 
Material, Table S9). The normality and 
linearity assumptions of our models held (data 
not shown). There was no material differ‑
ence in estimates from regression models 
fitted without influential observations (data 
not shown).
Discussion
We found that prenatal p,p´-DDE exposure 
was significantly associated with increased 
infant growth, and postnatal PCB‑153 
exposure with decreased infant growth. Our 
estimates suggest that, on average, children 
with a 388‑ng/g higher prenatal concentra‑
tion of p,p´-DDE would weigh approximately 
160 g more than other children at 24 months 
of age, whereas children with a 183‑ng/g 
higher postnatal concentration of PCB‑153 
would weigh approximately 140 g less.
Prenatal PCB‑153 concentrations were 
not significantly associated with infant 
growth. Because PCB‑153 is a proxy 
biomarker for a number of PCB congeners of 
varying toxicity (Glynn et al. 2000), inconsis‑
tent results from previous studies (i.e., Blanck 
et al. 2002; Cupul‑Uicab et al. 2010, 2013; 
Gladen et al. 2000; Hertz‑Picciotto et al. 
Table 2. Infant blood concentrations for PCB-153 and p,p’-DDE prenatal and postnatal exposure, estimated through pharmacokinetic modeling (ng/g lipid).
Study n
Prenatal PCB-153 < LOD 
n (%)
Postnatal PCB-153
n
Prenatal p,p’-DDE < LOD 
n (%)
Postnatal p,p’-DDE
Mean ± SD Median Mean ± SD Median Mean ± SD Median Mean ± SD Median
Duisburga 215 63.6 ± 45.9 56.7 0d 126.1 ± 98.8 108.7 215 141.4 ± 205.1 95.2 0d 255.3 ± 287.6 178.1
ELFEb 35 92.6 ± 41.9 83.3 0 301.1 ± 133.0 268.1 0 NA NA NA NA NA
FLEHS Ic 129 54.0 ± 38.4 41.3 6 (4.5)d 66.5 ± 69.6 47.1 130 214.7 ± 244.5 145.6 0d 272.6 ± 412.9 150.6
GRDc 321 184.7 ± 72.9 176.7 0 280.4 ± 152.0 252.4 0 NA NA NA NA NA
HUMISb 399 36.4 ± 17.1 33.1 0d 104.7 ± 52.2 96.8 399 63.4 ± 94.8 42.1 0d 177.3 ± 236.9 123.1
Michalovcec 880 164.4 ± 219.2 111.2 2 (0.2) 292.4 ± 425.4 175.3 880 540.5 ± 459.0 413.5 6 (0.7) 954.3 ± 1032.8 619.6
PELAGIEc 168 43.0 ± 31.5 32.1 0d 48.3 ± 55.9 26.2 168 73.5 ± 74.4 53.9 28 (16.4)d 75.7 ± 99.8 36.6
NA, not available. 
aPrenatal and postnatal concentrations estimated from maternal blood concentrations. bPrenatal and postnatal concentrations estimated from breast milk concentrations. cPrenatal 
and postnatal concentrations estimated from cord blood concentrations. dProvided LOQ instead of LOD.
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2005; Karmaus et al. 2009; Lamb et al. 2006; 
Mendez et al. 2011; Valvi et al. 2012, 2014; 
Verhulst et al. 2009; Warner et al. 2013) 
could be attributable to heterogeneity in the 
underlying PCB congeners mixture. Indeed, 
higher chlorinated PCBs have been associated 
with increased abdominal obesity in seniors, 
whereas the lower chlorinated PCBs showed 
an inverse relation (Lee et al. 2012).
The negative change in weight z‑score 
associated with postnatal PCB‑153 exposure 
is unlikely to be an an artifact of design (i.e., 
including weight in the pharmacokinetic 
model), because we did not find a significant 
association with postnatal p,p´‑DDE exposure. 
Grandjean et al. (2003) also reported attenu‑
ated growth of breastfed children exposed to 
major PCB congeners (138, 153, and 180) 
at 18 months. Concentrations in that study 
were higher than in ours, whereas total breast‑
feeding duration was similar. However, four 
other studies reported no significant associa‑
tions (Jacobson et al. 1990; Pan et al. 2010; 
Patandin et al. 1998; Rogan et al. 1987). 
Two studies investigated PCB concentra‑
tion in formula‑fed and breastfed babies 
(Jacobson et al. 1990; Patandin et al. 1998), 
whereas three estimated postnatal exposure 
simply as the product of PCB concentration 
and exclusive/total breastfeeding duration 
(Grandjean et al. 2003; Pan et al. 2010; 
Rogan et al. 1987). Exposure assessment that 
does not account for the dilution effect from 
weight increases in the growing child would 
lead to differential misclassification, over‑
estimating exposure in the heavier children. 
Therefore, this would bias results upward, 
and, if the association between PCB‑153 and 
growth is negative, could explain null findings 
reported in previous studies. The significant 
decline in birth weight of 150 g (95% CI: 
–250, –50) per 1‑μg/L increase in PCB‑153 
reported by Govarts et al. (2012) indicates 
that PCB‑153 may have a similar mode of 
action transplacentally and postnatally.
Prenatal p,p´-DDE exposure was signifi‑
cantly associated with increased change in 
weight‑for‑age z‑score, a positive trend seen in 
four of the five cohorts. A change in z‑score of 
0.12 is modest, below the 0.67 cut point for 
rapid growth (Monteiro and Victora 2005). 
Conversely, postnatal p,p´‑DDE exposure 
was not associated with infant growth, consis‑
tent with two previous studies (Pan et al. 
2010; Rogan et al. 1987). Two limitations 
apply when interpreting this evidence. First, 
we found significant heterogeneity when 
pooling the cohorts in the p,p´‑DDE analysis; 
however, fitting a more flexible model was 
not possible. Therefore, our estimate of 
the average effect does not account for the 
magnitude of variation among the cohorts. 
Second, although VIFs were < 5, variance 
doubled when prenatal and postnatal were 
mutually adjusted, suggesting collinearity. 
However, although our point estimate may be 
uncertain, the confidence intervals incorpo‑
rate uncertainty generated by any collinearity 
(Kleinbaum et al. 2013). The more appro‑
priate prenatal p,p´‑DDE estimate probably 
lies between the unadjusted and adjusted one.
Our p,p´‑DDE results are plausible. Most 
previous studies also found a positive asso‑
ciation between p,p´‑DDE and rapid growth 
and higher BMI in infancy (Mendez et al. 
2011; Valvi et al. 2014; Verhulst et al. 2009), 
overweight and BMI around 7 years (Valvi 
et al. 2012; Warner et al. 2013), and weight‑
for‑height at puberty in males (Gladen et al. 
2000) and in adulthood for females (Karmaus 
et al. 2009). Studies with high concentra‑
tions, however, reported no significant asso‑
ciations (Cupul‑Uicab et al. 2010, 2013; 
Garced et al. 2012; Gladen et al. 2004). This 
Table 3. Associations between total exposure from conception to 2 years to PCB-153 (152 ng/g) and 
p,p’-DDE (515 ng/g) and change in weight-for-age z-score.
Cohort
PCB-153 p,p’-DDE
n β (95% CI) n β (95% CI)
Duisburg 222 0.13 (–0.19, 0.46) 222 0.54 (0.22, 0.86)
ELFE 35 –0.19 (–0.74, 0.35) 0 NA
FLEHS I 134 0.06 (–0.50, 0.62) 134 0.05 (–0.22, 0.32)
GRD 588 –0.24 (–0.39, –0.09) 0 NA
HUMIS 399 –0.32 (–0.72, 0.08) 399 –0.26 (–0.56, 0.04)
Michalovce 938 0.01 (–0.02, 0.03) 938 0.02 (–0.02, 0.06)
PELAGIE 171 0.44 (–0.24, 1.12) 171 0.73 (–0.34, 1.81)
Pooled estimate (random) 2,487 –0.06 (–0.15, 0.03) 1,864 0.04 (–0.001, 0.07)
NA, not available. 
Results for both pooled sample and individual cohorts are per IQR increase for the pooled sample (ng/g lipid). Models 
were adjusted for birth weight, parity, gestational age, maternal smoking during pregnancy, maternal age at birth, 
maternal height and weight, Roma ethnicity and breastfeeding, and, for the pooled estimate, were fitted with random 
intercept (p,p’-DDE) and random intercept and slope (PCB-153) by cohort.
Figure 1. Associations between change in weight-for-age z-score and total exposure from conception 
to 2 years, prenatal exposure (unadjusted and adjusted for postnatal exposure) and postnatal exposure 
(unadjusted and adjusted for prenatal exposure) to (A) PCB-153 and (B) p,p’-DDE. Results are per IQR 
increase (ng/g lipid). PCB-153 IQRs: total exposure 152 ng/g, prenatal exposure 120 ng/g, postnatal 
exposure 183 ng/g. p,p’-DDE IQRs: total exposure 515 ng/g, prenatal exposure 388 ng/g, postnatal exposure 
571 ng/g. Models were adjusted for birth weight, parity, gestational age, maternal smoking during 
pregnancy, maternal age at birth, maternal height and weight, Roma ethnicity, and breastfeeding, and 
were fitted with random slope (p,p’-DDE) and slope (PCB-153) by cohort. Prenatal unadjusted: prenatal 
exposure adjusted for covariates except postnatal. Prenatal adjusted: prenatal exposure adjusted for 
covariates including postnatal. Postnatal unadjusted: postnatal exposure adjusted for covariates except 
prenatal. Postnatal adjusted: postnatal exposure adjusted for covariates including prenatal.
β (95% CI) nExposure
β (95% CI) nExposure
PCB total exposure –0.06 (–0.15, 0.03) 2,487
Prenatal unadjusted –0.001 (–0.07, 0.07) 2,487
Prenatal adjusted 0.05 (–0.05, 0.14) 2,487
Postnatal unadjusted –0.06 (–0.15, 0.02) 2,487
Postnatal adjusted –0.10 (–0.19, –0.01) 2,487
DDE total exposure 0.04 (–0.001, 0.07) 1,864
Prenatal unadjusted 0.07 (0.02, 0.12) 1,864
Prenatal adjusted 0.12 (0.03, 0.22) 1,864
Postnatal unadjusted 0.03 (–0.01, 0.06) 1,864
Postnatal adjusted –0.04 (–0.11, –0.02) 1,864
–0.2 –0.1 0 0.1 0.2
Change in z-score
–0.2 –0.1 0 0.1 0.2
Total exposure from
conception to 24 months
Prenatal exposure
Postnatal exposure
Change in z-score
Persistent organic pollutants and infant growth
Environmental Health Perspectives • volume 123 | number 7 | July 2015 735
could be a chance finding or could suggest a 
mode of action that operates at lower doses, 
in line with the nonmonotonic relationship 
seen between endocrine‑disrupting chemicals 
(EDCs) and hormones (Vandenberg et al. 
2012). No studies to date reported a negative 
effect of p,p´‑DDE on growth/BMI (Table S7 
in Cupul‑Uicab et al. 2013).
Our approach has strengths and limita‑
tions. We pooled data from seven European 
birth cohorts, examining associations between 
POPs and infant growth across larger samples 
of individuals with heterogeneous and distinct 
prenatal/postnatal exposure profiles. Compared 
with single‑cohort studies, the pooled design 
controls better for unmeasured confounding 
(including from other compounds), because 
the underlying confounder structure varies 
across cohorts. Furthermore, it reduces or 
eliminates reporting bias by showing results for 
all eligible European cohorts.
We attempted to isolate prenatal from 
postnatal exposure; however, as discussed, 
the p,p´‑DDE results suggest some collin‑
earity. To ascertain a closer estimate of 
prenatal exposure, we would ideally restrict 
our analyses to babies who were not breastfed. 
Too few cohorts had non‑breastfed babies 
(three for PCB‑153, two for p,p´-DDE), 
precluding meaningful sensitivity analyses.
Our postnatal exposure modeling was 
more appropriate than the simple models used 
in previous studies, which incorporated only 
breastfeeding. The pharmacokinetic model 
generated exposure profiles based on cord 
blood, maternal blood, or breast milk levels 
and known determinants of children’s blood 
concentration. This model was validated in 
Michalovce and an Inuit cohort with repeated 
POPs measurements: Estimated concentra‑
tions from the pharmacokinetic model 
explained from 40% to 83% of p,p´‑DDE 
and 51% to 81% of PCB‑153 measured in 
children’s blood at 6 and 16 months (Verner 
et al. 2013). Estimations based on maternal 
blood were better than cord blood estimations, 
which were better than breast milk estima‑
tions. Repeated samples for model validation 
(e.g., cord/child blood concentrations) were 
unavailable in other cohorts in this study. It 
may be that the model predictability is lower 
in these cohorts, and model accuracy is lower 
in cohorts with estimations made from cord 
blood/breast milk. Despite these limitations, 
pharmacokinetic modeling presents a major 
improvement on metrics that do not account 
for important parameters (i.e., change in 
child weight, breast milk consumption, or 
lipid content). We did not have POPs dietary 
exposure information; however, breastfeeding 
is the main determinant of infant blood 
concentrations (Ayotte et al. 2003). Few 
cohorts distinguished exclusive from partial 
breastfeeding; therefore, we used total duration 
and descriptions of breast milk consump‑
tion in the general population. Furthermore, 
information on gestational weight gain and 
weight changes after pregnancy—influential in 
sensitivity analyses (Verner et al. 2013)—were 
not available in most cohorts. These factors 
may have decreased model precision and could 
lead to small differential misclassification, over‑
estimating heavier children’s blood concentra‑
tions and resulting in a positive bias (in this 
case toward the null).
We added together the prenatal and post‑
natal exposure AUCs to assess total exposure 
from conception to 2 years, which has not 
been investigated in previous studies. Our 
prenatal AUC was calculated as the cord 
blood exposure estimate multiplied by gesta‑
tional age. Although prenatal concentrations 
would be influenced by maternal weight gain 
over pregnancy, which would vary the volume 
of distribution, this information was not 
available in some of the cohorts. Our prenatal 
AUC is not expected to be more biased than 
using cord blood concentration as a proxy 
for prenatal exposure. Furthermore, adjust‑
ment for maternal gestational weight gain in 
cohorts where this was available did not affect 
our results (data not shown).
We used lipid‑adjusted POP concentra‑
tions in our pharmacokinetic model, assuming 
an equilibrium across body lipids. Differential 
transport, or protection of the placenta or 
mammary gland due to molecular size, could 
require a conversion factor. However, consid‑
erable uncertainty is associated with conver‑
sion factors because of variability from factors 
other than differing measurement matrices 
(i.e., maternal body weight), which are not 
taken into account. Study‑specific conver‑
sion factors are also difficult to apply to other 
studies with differing distributions of under‑
lying co‑factors. We therefore decided against 
applying conversion factors.
In addition, we were not able to test for 
exposure to combinations of these POPs and 
other EDCs, and may have missed important 
mixture effects.
We modeled weight at 24 months using 
a mixed model for growth with cubic poly‑
nomials, standardizing the children’s weights 
using cohort‑specific data. Excessive infant 
growth between 0 and 24 months has previ‑
ously been identified as a risk factor for 
obesity at a later age (Monteiro and Victora 
2005). We did not test growth from birth 
to 6 months or 12 months because only four 
cohorts had appropriate measurements, and 
possibly missed a critical window for growth 
trajectory (Botton et al. 2008).
We did not have information on fatty 
fish intake in all cohorts; however, restricting 
analysis to the four cohorts where this was 
available revealed no material difference (data 
not shown).
Breastfeeding duration unadjusted for 
other covariates is associated with reduced 
growth in our study. Breastfeeding is an 
important contributor to postnatal POP 
exposure and relates to nutritional intake and 
other socioeconomic factors. However, addi‑
tional adjustment for breastfeeding duration 
in the postnatal PCB‑153 model had limited 
impact on the estimates (i.e., β = –0.12; 95% 
CI –0.21, –0.03 vs. β = –0.10; 95% CI –0.19, 
–0.01). Breastfeeding reduced the estimated 
increase in infant growth from prenatal 
p,p´-DDE by 14% (i.e., β = 0.14; 95% CI: 
0.06, 0.22 vs. β = 0.12; 95% CI: 0.03, 0.22), 
possibly reflecting increased PCB‑153 
breastfeeding exposure.
Michalovce is a large cohort, accounting 
for 38% (PCB‑153) and 50% (p,p´‑DDE) of 
our total population. Although Michalovce 
drives the precision of the associations, 
these relations held after removing these 
children from the analyses. The postnatal 
PCB‑153 and prenatal p,p´‑DDE estimates 
became nonsignificant, as expected with a 
large sample size reduction, and the latter 
doubled in size.
Conclusion
In a large and heterogeneous European popu‑
lation, we found an increase in infant growth 
associated with prenatal p,p´-DDE and a 
decrease associated with postnatal PCB‑153 
exposure. To understand the importance 
of POPs breastfeeding exposure on health, 
future investigations should assess both 
prenatal and postnatal exposure.
RefeRences
Arcus-Arth A, Krowech G, Zeise L. 2005. Breast milk 
and lipid intake distributions for assessing cumu-
lative exposure and risk. J Expo Anal Environ 
Epidemiol 15:357–365; doi:10.1038/sj.jea.7500412.
Ayotte P, Muckle G, Jacobson JL, Jacobson SW, 
Dewailly É, Inuit Cohort Study. 2003. Assessment 
of pre- and postnatal exposure to polychlori-
nated biphenyls: lessons from the Inuit Cohort 
Study. Environ Health Perspect 111:1253–1258; 
doi:10.1289/ehp.6054.
Blanck HM, Marcus M, Rubin C,  Tolbert  PE, 
Hertzberg VS, Henderson AK, et al. 2002. Growth in 
girls exposed in utero and postnatally to polybro-
minated biphenyls and polychlorinated biphenyls. 
Epidemiology 13:205–210.
Botton J, Heude B, Maccario J, Ducimetière P, 
Charles MA, FLVS Study Group. 2008. Postnatal 
weight and height growth velocities at different 
ages between birth and 5 y and body composi-
tion in adolescent boys and girls. Am J Clin Nutr 
87:1760–1768.
Chevrier C, Warembourg C, Gaudreau E, Monfort C, 
Le Blanc A, Guldner L, et al. 2013. Organochlorine 
pesticides, polychlorinated biphenyls, seafood 
consumption, and time-to-pregnancy. Epidemiology 
24:251–260.
Cupul-Uicab LA, Hernández-Avila M, Terrazas-
Medina EA, Pennell ML, Longnecker MP. 2010. 
Prenatal exposure to the major DDT metabolite 
Iszatt et al.
736 volume 123 | number 7 | July 2015 • Environmental Health Perspectives
1,1-dichloro-2,2-bis(p-chlorophenyl)ethylene (DDE) 
and growth in boys from Mexico. Environ Res 
110:595–603; doi:10.1016/j.envres.2010.06.001.
Cupul -Uicab LA,  K lebanof f  MA,  Brock  JW, 
Longnecker MP. 2013. Prenatal exposure to persis-
tent organochlorines and childhood obesity in the 
U.S. Collaborative Perinatal Project. Environ Health 
Perspect 121:1103–1109; doi:10.1289/ehp.1205901.
Eggesbø M, Stigum H, Longnecker MP, Polder A, 
Aldrin M, Basso O, et al. 2009. Levels of hexa-
chlorobenzene (HCB) in breast milk in relation to 
birth weight in a Norwegian cohort. Environ Res 
109:559–566.
Garced S, Torres-Sánchez L, Cebrián ME, Claudio L, 
López-Carrillo L. 2012. Prenatal dichlorodiphenyl-
dichloroethylene (DDE) exposure and child growth 
during the first year of life. Environ Res 113:58–62; 
doi:10.1016/j.envres.2011.12.002.
Gladen BC, Klebanoff MA, Hediger ML, Katz SH, 
Barr  DB, Davis MD, et  al. 2004. Prenatal DDT 
exposure in relation to anthropometric and pubertal 
measures in adolescent males. Environ Health 
Perspect 112:1761–1767; doi:10.1289/ehp.7287.
Gladen BC, Ragan NB, Rogan WJ. 2000. Pubertal 
growth and development and prenatal and lacta-
tional exposure to polychlorinated biphenyls 
and dichlorodiphenyl dichloroethene. J Pediatr 
136:490–496; doi:10.1016/S0022-3476(00)90012-X.
Glynn AW, Wolk A, Aune M, Atuma S, Zettermark S, 
Maehle-Schmid M, et al. 2000. Serum concen-
trations of organochlorines in men: a search for 
markers of exposure. Sci Total Env 263:197–208; 
doi:10.1016/S0048-9697(00)00703-8.
Govarts E, Nieuwenhuijsen M, Schoeters G, Ballester F, 
Bloemen K, de Boer M, et al. 2012. Birth weight 
and prenatal exposure to polychlorinated biphe-
nyls (PCBs) and dichlorodiphenyldichloroethylene 
(DDE): a meta-analysis within 12 European birth 
cohorts. Environ Health Perspect 120:162–170; 
doi:10.1289/ehp.1103767.
Grandjean P, Budtz-Jørgensen E, Steuerwald  U, 
Heinzow  B, Needham LL, Jørgensen PJ, et  al. 
2003. Attenuated growth of breast-fed children 
exposed to increased concentrations of methyl-
mercury and polychlorinated biphenyls. FASEB J 
17:699–701; doi:10.1096/fj.02-0661fje.
Hertz-Picciotto I, Charles MJ, James RA, Keller JA, 
Willman E, Teplin S. 2005. In utero polychlorinated 
biphenyl exposures in relation to fetal and early 
childhood growth. Epidemiology 16:648–656; 
doi:10.1097/01.ede.0000173043.85834.f3.
Hertz-Picciotto I, Trnovec T, Kocan A, Charles  M, 
Ciznar P, Langer P, et al. 2003. PCBs and early 
childhood development in Slovakia: study design 
and background. Fresenius Environ Bull 12:208–214.
Hornung RW, Reed LD. 1990. Estimation of average 
concentration in the presence of nondetectable 
values. Appl Occup Environ Hyg 5:46–51; doi:10.1080
/1047322X.1990.10389587.
Huisman M, Koopman-Esseboom C, Fidler V, Hadders-
Algra M, van der Paauw C, Tuinstra L, et al. 1995. 
Perinatal exposure to polychlorinated biphenyls 
and dioxins and its effect on neonatal neurological 
development. Early Hum Dev 41:111–127.
Jacobson JL, Jacobson SW, Humphrey HE. 1990. Effects 
of exposure to PCBs and related compounds on 
growth and activity in children. Neurotoxicol Teratol 
12:319–326; doi:10.1016/0892-0362(90)90050-M.
Karmaus W, Osuch JR, Eneli I, Mudd LM, Zhang J, 
Mikucki  D, et  al.  2009. Maternal levels of 
dichlorodiphenyl-dichloroethylene (DDE) may 
increase weight and body mass index in adult 
female offspring. Occup Environ Med 66:143–149; 
doi:10.1136/oem.2008.041921.
Kleinbaum DG, Kupper LL, Nizam A, Rosenerg ES. 2013. 
Applied Regression Analysis and Other Multivariable 
Methods. 5th ed. Boston:Cengage Learning.
Koppen G, Den Hond E, Nelen V, Van De Mieroop E, 
Bruckers L, Bilau M, et al. 2009. Organochlorine 
and heavy metals in newborns: results from the 
Flemish Environment and Health Survey (FLEHS 
2002–2006). Environ Int 35:1015–1022.
Lamb MR, Taylor S, Liu X, Wolff MS, Borrell L, Matte TD, 
et al. 2006. Prenatal exposure to polychlorinated 
biphenyls and postnatal growth: a structural 
analysis. Environ Health Perspect 114:779–785; 
doi:10.1289/ehp.8488.
La Merrill M, Birnbaum LS. 2011. Childhood obesity 
and environmental chemicals. Mt Sinai J Med 
78:22–48; doi:10.1002/msj.20229.
Lee DH, Lind L, Jacobs DR Jr, Salihovic S, van Bavel B, 
Lind PM. 2012. Associations of persistent organic 
pollutants with abdominal obesity in the elderly: 
the Prospective Investigation of the Vasculature 
in Uppsala Seniors (PIVUS) study. Environ Int 
40:170–178; doi:10.1016/j.envint.2011.07.010.
Longnecker MP, Korrick SA, Moysich KB. 2003. 
Human health effects of polychlorinated biphe-
nyls. In: Dioxins and Health, 2nd ed. (Schecter A, 
Gasiewicz TA, eds). Hoboken, NJ:John Wiley & 
Sons Inc., 679–728.
Mendez MA, Garcia-Esteban R, Guxens M, Vrijheid M, 
Kogevinas M, Goñi F, et al. 2011. Prenatal organo-
chlorine compound exposure, rapid weight 
gain, and overweight in infancy. Environ Health 
Perspect 119:272–278; doi:10.1289/ehp.1002169.
Monteiro POA, Victora CG. 2005. Rapid growth 
in infancy and childhood and obesity in later 
life—a systematic review. Obes Rev 6:143–154; 
doi:10.1111/j.1467-789X.2005.00183.x.
Pan IJ,  Daniels  JL,  Herr ing AH,  Rogan WJ, 
Siega-Riz AM, Goldman BD, et al. 2010. Lactational 
exposure to polychlorinated biphenyls, dichloro-
diphenyltrichloroethane, and dichlorodiphenyl-
dichloroethylene and infant growth: an analysis 
of the Pregnancy, Infection, and Nutrition Babies 
Study. Paediatr Perinat Epidemiol 24:262–271; 
doi:10.1111/j.1365-3016.2010.01114.x.
Patandin S, Koopman-Esseboom C, de Ridder MA, 
Weisglas-Kuperus  N, Sauer PJ. 1998. Effects 
of environmental exposure to polychlorinated 
biphenyls and dioxins on birth size and growth 
in Dutch Children. Pediatr Res 44:538–545; 
doi:10.1203/00006450-199810000-00012.
Phillips DL, Pirkle JL, Burse VW, Bernert JT  Jr, 
Henderson LO, Needham LL. 1989. Chlorinated 
hydrocarbon levels in human serum: effects of 
fasting and feeding. Arch Environ Contam Toxicol 
18:495–500; doi:10.1007/BF01055015.
Ritter R, Scheringer M, MacLeod M, Moeckel C, 
Jones K, Hungerbühler K. 2011. Intrinsic human 
elimination half-lives of polychlorinated biphenyls 
derived from the temporal evolution of cross-
sectional biomonitoring data from the United 
Kingdom. Environ Health Perspect 119:225–231; 
doi:10.1289/ehp.1002211.
Rogan WJ, Gladen BC, McKinney JD, Carreras N, 
Hardy  P, Thullen J, et  al. 1987. Polychlorinated 
biphenyls (PCBs) and dichlorodiphenyl dichloro-
ethene (DDE) in human milk: effects on growth, 
morbidity, and duration of lactation. Am J Public 
Health 77:1294–1297.
Rubin DB. 1987. Multiple Imputation for Nonresponse 
in Surveys. New York:John Wiley & Sons Inc.
Stockholm Convention. 2001. Stockholm Convention 
on Persistent Organic Pollutants. Geneva:United 
Nations Environment Program. Available: http://
chm.pops.int/Portals/0/Repository/convention_
text/UNEP-POPS-COP-CONVTEXT-FULL.English.
PDF [accessed 12 May 2014].
Valvi D, Mendez MA, Garcia-Esteban R, Ballester F, 
Ibarluzea J, Goñi F, et al. 2014. Prenatal exposure 
to persistent organic pollutants and rapid weight 
gain and overweight in infancy. Obesity (Silver 
Spring) 22:488–496; doi:10.1002/oby.20603.
Valvi D, Mendez MA, Martinez D, Grimalt J, Torrent M, 
Sunyer J, et al. 2012. Prenatal concentrations of 
polychlorinated biphenyls, DDE, and DDT and 
overweight in children: a prospective birth cohort 
study. Environ Health Perspect 120:451–457; 
doi:10.1289/ehp.1103862.
van Buuren S. 2007. Multiple imputation of discrete 
and continuous data by fully conditional speci-
fication. Stat Methods Med Res 16:219–242; 
doi:10.1177/0962280206074463.
Vandenberg LN, Colborn T, Hayes TB, Heindel JJ, 
Jacobs DR Jr, Lee DH, et al. 2012. Hormones and 
endocrine-disrupting chemicals: low-dose effects 
and nonmonotonic dose responses. Endocr Rev 
33:378–455; doi:10.1210/er.2011-1050.
Vandentorren S, Bois C, Pirus C, Sarter H, Salines G, 
Leridon  H, et  al. 2009. Rationales, design and 
recruitment for the Elfe longitudinal study. BMC 
Pediatr 9:58; doi:10.1186/1471-2431-9-58.
Verhulst SL, Nelen V, Hond ED, Koppen G, Beunckens C, 
Vael C, et al. 2009. Intrauterine exposure to envi-
ronmental pollutants and body mass index during 
the first 3 years of life. Environ Health Perspect 
117:122–126; doi:10.1289/ehp.0800003.
Verner MA, Sonneborn D, Lancz K, Muckle G, Ayotte P, 
Dewailly É, et al. 2013. Toxicokinetic modeling of 
persistent organic pollutant levels in blood from 
birth to 45 months of age in longitudinal birth cohort 
studies. Environ Health Perspect 121:131–137; 
doi:10.1289/ehp.1205552.
Walkowiak J, Wiener J, Fastabend A, Heinzow  B, 
Krämer U, Schmidt E, et al. 2001. Environmental 
exposure to polychlorinated biphenyls and quality 
of the home environment: effects on psychodevel-
opment in early childhood. Lancet 358:1602–1607.
Warner M, Aguilar Schall R, Harley KG, Bradman A, 
Barr D, Eskenazi B. 2013. In utero DDT and DDE 
exposure and obesity status of 7-year-old Mexican-
American children in the CHAMACOS cohort. 
Environ Health Perspect 121:631–636; doi:10.1289/
ehp.1205656.
Wilhelm M, Wittsiepe J, Lemm F, Ranft U, Krämer U, 
Fürst  P, et  al. 2008. The Duisburg birth cohort 
study: influence of the prenatal exposure to PCDD/
Fs and dioxin-like PCBs on thyroid hormone status 
in newborns and neurodevelopment of infants 
until the age of 24 months. Mutat Res 659:83–92.
Wittsiepe J, Schrey P, Lemm F, Eberwein G, Wilhelm M. 
2008. Polychlorinated dibenzo-p-dioxins/polychlo-
rinated dibenzofurans (PCDD/Fs), polychlorinated 
biphenyls (PCBs), and organochlorine pesticides 
in human blood of pregnant women from Germany. 
J Toxicol Environ Health A 71:703–709.
Wolff MS, Zeleniuch-Jacquotte A, Dubin N, Toniolo P. 
2000. Risk of breast cancer and organochlorine 
exposure. Cancer Epidemiol Biomarkers Prev 
9:271–277.
